To evaluate combination therapy with a PARP inhibitor, O’Reilly et al. conducted a phase I trial of GEM/CDDP plus veliparib for 17 patients with untreated advanced PC, including 9 cases harboring germline BRCA1/BRCA2 mutation, and reported an ORR of 77.8% and median OS of 23.3 months in BRCA-mutated cases [90]. This evidence concerns the gene BRCA1 and pachyonychia congenita.